Neuroblastoma screening

	Neuroblastoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Neuroblastoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Neuroblastoma screening On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Neuroblastoma screening All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Neuroblastoma screening
CDC on Neuroblastoma screening
Neuroblastoma screening in the news
Blogs on Neuroblastoma screening
Directions to Hospitals Treating Neuroblastoma
Risk calculators and risk factors for Neuroblastoma screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2] Zahir Ali Shaikh, MD [3]

Overview

There is insufficient evidence to recommend the routine screening for neuroblastoma as it has no mortality benefits.

There is insufficient evidence to recommend the routine screening for neuroblastoma by measuring the vanillylmandelic acid and homovanillic acid at 6 months or 1 year or age, as it does not have the mortality benefits.^[1]^[2]